Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study

Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study

ObjectiveThis study mainly observes the efficacy and safety of almonertinib plus chemotherapy compared with almonertinib alone in the second-line treatment of advanced non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR).MethodsIn this study, clinical data of 68 pa...

Full description

Bibliographic Details
Main Authors: Xiaoxu Fang, Yan Xiang, Kaihua Lu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Oncology
Subjects:
almonertinib
non-small cell lung cancer
epidermal growth factor receptor mutation
chemotherapy
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1248690/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1248690/full

Similar Items